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under the CC BY-NC-ND license (http:Abstract Recent innovations in thulium laser techniques have allowed application in the
treatment of bladder cancer. Laser en bloc resection of bladder cancer is a transurethral pro-
cedure that may offer an alternative to the conventional transurethral resection procedure.
We conducted a review of basic thulium laser physics and laser en bloc resection procedures
and summarized the current clinical literature with a focus on complications and outcomes.
Literature evidence suggests that thulium laser techniques including smooth incision, tissue
vaporization, and en bloc resection represent feasible, safe, and effective procedures in the
treatment of bladder cancer. Moreover, these techniques allow improved specimen orientation
and accurate determination of invasion depth, facilitating correct diagnosis, restaging, and re-
evaluation of the need for a second resection. Nonetheless, large-scale multicentre studies
with longer follow-up are warranted for a robust assessment. The present review is meant
as a quick reference for urologists.
ª 2016 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Bladder cancer is the 11th most commonly diagnosed can-
cer worldwide. Approximately 75% of patients with bladder
cancer present with non-muscle-invasive bladder cancer
(NMIBC), confined to the mucosa (stage Ta, carcinoma in
situ) or submucosa (stage T1) [1]. Transurethral resection
of bladder tumor (TURBT) remains the gold standard
treatment for bladder cancer. However, this type of.com (H. Liu), xsjurologist@163.c
f Second Military Medical Univers
.05.002
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//creativecommons.org/licenses/procedure is associated with a significant risk of residual
tumors, which are often under-staged after initial TURBT.
According to the guidelines [1], persistent disease after
resection of T1 tumors has been observed in 33%e55% of
patients, and after resection of Ta Grade 3 tumor in 41.4%.
The likelihood that muscle-invasive disease is detected by
second resection of initially T1 tumor ranges from 4% to
25%, and it increases to 45% if there was no muscle in the
initial resection. While complete and correct tumor resec-
tion is crucial to achieve a good prognosis, conventionalom (S. Xia).
ity.
ion and hosting by Elsevier B.V. Ltd. This is an open access article
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Thulium laser for bladder cancer 131TURBT results in greater risk of recurrence. In order to
overcome the limitations of conventional TURBT, various
modifications of standard resection techniques have
recently been developed. An important development is
represented by transurethral thulium laser en bloc resec-
tion of bladder tumor (ThuLEBT), along with a catalogue of
techniques based on other lasers, such as holmium laser
(Ho:YAG) vaporization or en bloc resection of bladder
tumor [2,3].
Although various laser types have been used in the
treatment of bladder cancer, holmium and thulium lasers
are most frequently employed. Similar results have been
reported for both types of lasers with respect to feasibility,
safety, and effectiveness in comparison with TURBT. How-
ever, the continuous beam of the thulium laser does not
exhibit the tissue-tearing effect of the pulsed emissions of
Ho:YAG, which is likely. This might be the reason for the
exclusive application of the thulium laser for en bloc
resection, while no application has been reported for
vaporization of bladder cancer [4]. Thus, in the present
review, we focused on ThuLEBT, a state-of-the-art tech-
nique for minimally invasive treatment of bladder tumors.
2. Technological and procedural details
2.1. Thulium laser
The thulium laser is a continuous wave that emits at a wave
length of approximately 2013 nm. Its physical properties
and effect on various tissues are virtually identical to those
of the Ho:YAG, but with an even shallower depth (0.25 mm)
of tissue penetration [5]. Due to the pattern of the
continuous wave, the thulium laser allows smooth incision
and vaporization of tissues with excellent efficiency [6].
Thulium laser devices with shallow penetration and power
settings that can be adjusted according to tumor size pro-
vide relatively clear vision and satisfactory haemostatic
effect during the operation. Under these circumstances,
thulium laser-based techniques allow en bloc resection and
ablation for the management of bladder tumors [7].
2.2. Thulium laser operation procedure
Several studies have reported on the operating procedure
for the treatment of bladder cancer. Thulium lasers are
usually generated using a 2-mm laser system (LISA laser
products OHG, Katlenburg-Lindau, Germany) with a 2013-
nm laser fibre. Laser energy can be delivered in continuous
mode via a 550-mm fibre with a power of 5e15 W or
30e50 W, through a 24 Fr or 26 Fr 30-degree continuous
flow endoscope [6,8e10].
Once the laser starts to operate, the laser fibre is held at
a safety margin of 2e5 mm away from the tumor, which is
sufficient for the laser energy to instantly vaporize the
tumor. The efficiency of vaporization is proportional to the
laser power, though using higher power does not lead to an
increase in complication rates [3]. In order to complete the
en bloc resection and obtain an adequate specimen, it has
been suggested that, after finishing the surrounding line,
the operation should proceed with a transurethral resec-
tion, to expose the base of the tumor up to the deeperlayers, until the detrusor muscle is exposed; finally, the
bladder wall is dissected via blunt laser incision. Larger
tumors (size >3 cm) can be removed through the base of
the bladder wall after being cut into two or three pieces.
Saline irrigation is used throughout the procedure
[6,8,11,12].
Once the tumors are removed, random, cold-cut biopsy
specimens are taken from the tumor base and from an area
within 2 cm of the tumor edge; the biopsy specimens must
be harvested from areas which have adequately coagulated
or been vaporized using laser energy, after removing the
surrounding muscle layer.
3. Clinical outcomes
To assess the clinical outcomes associated with ThuLEBT,
the present review noted the reported operative duration,
perioperative complications, and tumor recurrence.
3.1. Operation time and complications
Based on the systematic review and meta-analysis
regarding the management of NMIBC, Bai et al. [3] found
no significant difference between thulium laser treatment
and TURBT or Ho:YAG treatment with respect to operation
time or hospitalization duration (mean difference: 0.69 h;
95% confidence interval (CI): 1.62e0.24 h; p Z 0.14).
However, Zhang et al. [11] and Chen et al. [13] found that
operation time was significantly lower for patients under-
going TURBT than for those undergoing ThuLEBT (28.43 min
vs. 31.5 min, pZ 0.044; 56.5 min vs. 41.0 min, pZ 0.017;
respectively), which may have been due to the additional
time required for the thulium laser to achieve a precise
resection of the anterior wall of large tumors. Migliari et al.
[12] reported a mean operative time of 25 min (range,
12e30 min) for resection of a single papillary tumor with a
diameter of 2.5 cm (range, 0.5e4.5 cm), regardless of
tumor location. For multiple NMIBCs, Liu et al. [8] found the
mean operation time was 48 min per patient (range,
20e90 min), and 13.6 min per tumor (range, 5e25 min), the
mean number and diameter of tumors were 3 cm (range,
2e5 cm) and 1.2 cm (range, 0.3e2.5 cm), respectively.
With respect to intra- and post-operative complications,
Bai et al. [3] performed a systematic meta-analysis of seven
studies and found that ThuLEBT was better than TURBT.
Specifically, significant differences were observed between
the group of patients treated by ThuLEBT and the group of
patients treated by TURBT, with respect to obturator nerve
reflex (risk ratio: 0.07; 95%CI: 0.02e0.23; p < 0.0001),
bladder perforation (risk ratio: 0.16; 95%CI: 0.05e0.54;
p Z 0.003), bladder irrigation (risk ratio: 0.36; 95%CI:
0.19e0.69; pZ 0.002), and duration of the catheterization
(mean difference: 1.26 min; 95%CI: 1.79e(0.73) min;
p < 0.00001). Indeed, complications after ThuLEBT have
been described in only five studies, with a total of 355 pa-
tients. Specifically, bladder perforation in conjunction en
bloc resection was described in two studies, urethral stric-
ture was described in two studies, and anterior urethral
injury causedby transurethral resectionwas described in one
study. The overall complication rate was 1.4%, and none of
the complications were life-threatening. Acute peri- and
132 W. Wang et al.post-operative bleeding was not mentioned in any of these
studies. Taken together, these observations support the
conclusion that thulium laser treatment represents a safe
and efficient approach for managing bladder cancer.
3.2. Histopathological examination
Complete and correct tumor resection is essential in order
to achieve a good prognosis. However, TURBT often causes
fragmentation, artefacts, thermal damage, and tangential
sections that might hamper the histopathological evalua-
tion [14]. The thulium laser allows en bloc excision of tu-
mors with excellent haemostasis and a clearer visual field;
these features improve specimen orientation and enable
the detrusor muscle to be clearly visible during blunt
dissection [7]. Furthermore, histological reporting is more
straight forward, and it can allow accurate reporting of the
depth of invasion [4,12].
In terms of staging and grading,Wolters et al. [6], Liu et al.
[8], and Migliari et al. [12] all found that 100% of the biopsy
specimens contained detrusor muscle tissue suitable for
correct staging. However, Zhang et al. [11] found that, of 27
specimens that did not contain detrusor muscles, nine
specimens (6.3%, n Z 143) came from patients undergoing
TURBT, while 18 specimens (12.1%, nZ 149) came from pa-
tients undergoing ThuLEBT. In addition, Kramer et al. [15]
compared (pZ 0.18) the content of detrusor muscle tissue
in specimens harvested following electrical (nZ 150, 96.2%)
and laser (n Z 65, 100%) en bloc transurethral resection.
While the outcomes of these studieswere clear, the reported
differences did not reach statistical significance.
3.3. Tumor recurrence and progression
To date, no large, prospective, multi-centred studies with
long follow-upperiodshavebeenconducted to investigate the
efficiency of ThuLEBT. Based on currently available data,
recurrence rates after ThuLEBT are expected to be similar or
lower than those after Ho:YAG treatment or TURBT [3]. Liu
et al. [16] first presenteddata fromthe12-, 24-, and36-month
follow-up, with no difference between the group of patients
who had undergone ThuLEBT (10.9%, 19.5%, and 31.3%,
respectively) and the group of patients who had undergone
TURBT(10.7%,22.9%,and33.9%; respectively). Ina later study
on the clinical outcomes of ThuLEBT, Ho:YAG, and TURBT, the
same authors found that the currency rate at the 12-month
follow-up was lowest in patients who had undergone Thu-
LEBT (thulium laser: 12%, TURBT: 17.2%, Ho:YAG: 25%) [8].
Zhong et al. [17] found that recurrence rate at the 24-month
follow-up was similar between the patients who had under-
gone ThuLEBT (26.67%) or Ho:YAG treatment (24%), but lower
than that for patients who had undergone TURBT (30.95%).
According to KaplaneMeier survival curves from a recent
study conducted by Chen et al. [13], there was no statistical
difference between ThuLEBT and TURBTwith respect to the
rate of recurrence at the 18-month follow-up (p Z 0.383).
Zhang et al. [11] found that overall recurrence rate was
14.7%, 42.1%, and 62.5% in low risk, intermediate-low risk,
and intermediate-high risk subgroups, respectively. How-
ever, none of these studies used a systematic classification
system for assessing recurrence and progression, especiallywith long-term follow-up. Hence, future studies should use
a standard classification scheme and gather results from
long-term follow-up periods.
3.4. Second resection
The risk of residual tumor and frequent under-staging after
initial TURBT has been demonstrated. A second TURBT,
usually performed within 2e6 weeks of the primary pro-
cedure, is always recommended in certain cases such as T1
bladder tumors. The potential advantages of thulium laser
treatment, as previously mentioned, include accurate
reporting of the depth of invasion, which serves for deter-
mining the correct diagnosis. This opens away to re-
evaluate the need for a second resection or for the
restaging of bladder tumors in the short term. Migliari et al.
[12] found that re-resection and cold cup biopsy of the
tumor base at 90 days postoperatively was negative for
bladder tumor persistence or recurrence in all 58 patients
who had received thulium laser treatment; however, seven
of 61 patients who had undergone TURBT were found to be
tumor-positive, and 3 of these patients were upstaged.
These results support the conclusion that employing
thulium laser treatment has the potential of avoiding a
second resection for 90 days postoperatively. However,
further studies with long-term follow-up are warranted in
order to thoroughly support these findings.
4. Conclusion
Newly developed, high-performance techniques based on
thulium laser represent safe and efficient procedures for
treating bladder cancer. There was no significant differ-
ence between ThuLEBT and TURBT with respect to tumor
recurrence and progression rates. Furthermore, ThuLEBT is
advantageous because it allows complete tumor resection
and straight forward histological evaluation of specimens,
enabling to re-evaluate the need for a second resection or
for restaging the bladder tumor in the short term. Large,
prospective, multicentre studies with longer follow-up pe-
riods should be performed to systematically confirm the
advantages of thulium laser applications for treating
bladder cancer.Conflicts of interest
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